1hon MSN
In an international collaboration, researchers have made an important breakthrough in the therapeutic delivery of microRNAs ...
Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...
Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...
9h
GlobalData on MSNSuccess for YolTech’s hyperoxaluria in vivo gene therapy in early-stage trialYolTech's gene therapy is intended as a one-time life-long cure for patients living with PH1, which can lead to kidney ...
The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...
Physical therapy can help maintain muscle ... MedlinePlus. DMD gene. MedlinePlus. Duchenne muscular dystrophy. National Human Genome Research Institute. About Duchenne muscular dystrophy.
Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...
Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin ...
Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...
The scientists demonstrate that it is possible to specifically deliver the treatment to the muscle stem cells, avoiding ...
Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results